Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile
EA Wammes-van der Heijden,
CC Tijssen,
ACG Egberts,
EA Wammes-van der Heijden
Department of Clinical Pharmacy, University Medical Centre Utrecht,
Search for more papers by this authorCC Tijssen
Department of Neurology, St Elisabeth Hospital Tilburg, and
Search for more papers by this authorACG Egberts
Department of Clinical Pharmacy, University Medical Centre Utrecht,
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorEA Wammes-van der Heijden,
CC Tijssen,
ACG Egberts,
EA Wammes-van der Heijden
Department of Clinical Pharmacy, University Medical Centre Utrecht,
Search for more papers by this authorCC Tijssen
Department of Neurology, St Elisabeth Hospital Tilburg, and
Search for more papers by this authorACG Egberts
Department of Clinical Pharmacy, University Medical Centre Utrecht,
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorProf. Dr Antoine C. G. Egberts, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands. Tel. + 31-30-253-7324, fax + 31-30-253-9166, e-mail [email protected]
Abstract
Treatment patterns in migraine patients with cardiovascular risk factors are largely unknown. A retrospective observational study was conducted to characterize the baseline cardiovascular risk profile of new users of specific abortive migraine drugs, and to investigate treatment choices and patterns in patients with and without a known cardiovascular risk profile. New users of a triptan, ergotamine or Migrafin® (n = 36 839) from 1 January 1990 to 31 December 2006 were included. Approximately 90% of all new users did not have a clinically recognized cardiovascular risk profile. The percentage of new users with a cardiovascular risk profile did not differ between new users of a triptan, ergotamine or Migrafin® and also did not change during the study period of 17 years. Differences in treatment choices and patterns between migraine patients with and without a known cardiovascular risk profile reveal a certain reticence in prescribing vasoconstrictive antimigraine drugs to patients at cardiovascular risk.
References
- 1 Yasue H, Omote S, Takizawa A, Nagao M. Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm. Angiology 1981; 32: 414–18.
- 2 Galer BS, Lipton RB, Solomon S, Newman LC, Spierings EL. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache 1991; 31: 446–50.
- 3 Meyler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5–10.
- 4 Senter HJ, Lieberman AN, Pinto R. Cerebral manifestations of ergotism. Report of a case and review of the literature. Stroke 1976; 7: 88–92.
- 5 Hillis WS, Macintyre PD. Sumatriptan and chest pain. Lancet 1993; 341: 1564–5.
- 6 Ottervanger JP, Van Witsen TB, Valkenburg HA, Grobbee DE, Stricker BH. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994; 47: 305–9.
- 7
Visser WH,
Jaspers NM,
De Vriend RH,
Ferrari MD.
Chest symptoms after sumatriptan: a two year clinical practice review in 735 consecutive migraine patients.
Cephalalgia
1996; 16: 554–9.
10.1046/j.1468-2982.1996.1608554.x Google Scholar
- 8 O'Quinn S, Davis RL, Gutterman DL, Pait GD, Fox AW. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999; 19: 223–31.
- 9 Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 2000; 20: 687–95.
- 10 Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH. Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861–2.
- 11 Kelly M. Cardiac arrest following use of sumatriptan. Neurology 1995; 45: 1211–13.
- 12 O'Connor O, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995; 45: 2274–6.
- 13 Main ML, Ramaswamy K, Andrews TC. Cardiac arrest and myocardial infarction immediately after sumatriptan injection. Ann Intern Med 1998; 128: 874.
- 14 Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 1994; 343: 1105–6.
- 15 Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 1995; 21: 82–3.
- 16 Knudsen JF, Friedman B, Chen M, Goldwasser JE. Ischemic colitis and sumatriptan use. Arch Intern Med 1998; 158: 1946–8.
- 17 Liu JJ, Ardolf JC. Sumatriptan-associated mesenteric ischemia. Ann Intern Med 2000; 132: 597.
- 18 Schwartz DC, Smith DJ. Colonic ischemia associated with naratriptan use. J Clin Gastroenterol 2004; 38: 790–2.
- 19 Dodick DW, Martin VT, Smith T, Silberstein M. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 (Suppl. 1): 20–30.
- 20 Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44: 642–51.
- 21 Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine. The risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563–8.
- 22 Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM, Tijssen CC, Egberts ACG. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006; 67: 1128–34.
- 23 Herings RMC, Bakker A, Stricker BHC, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136–40.
- 24 URL http://www.pharmo.nl[Last accessed 26 March 2008.
- 25 Rahimtoola H, Egberts AC, Buurma H, Tijssen CC, Leufkens HG. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997. Cephalalgia 2001; 21: 596–603.
- 26 Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M. Triptan use and risk for cardiovascular events: a nested case–control study from the French health system database. Eur J Clin Pharmacol 2007; 63: 801–7.
- 27 Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
- 28 Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006; 29: 1263–8.
- 29 Rinaldi R, Vignatelli L, Galeotti M, Azzimondi G, De Carolis P. Accuracy of ICD-9 codes in identifying ischemic stroke in the General Hospital of Lugo di Romagna (Italy). Neurol Sci 2003; 24: 65–9.
- 30 Benesch C, Witter Jr DM, Wilder AL, Duncan PW, Samsa GP, Matchar DB. Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 1997; 49: 660–4.
- 31 Scher AI, Terwindt GM, Picavet HSJ, Verschuren WMM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine. The GEM population-based study. Neurology 2005; 64: 614–20.
- 32 Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006; 296: 283–91.
- 33 Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007; 167: 795–801.
- 34 Young WB, Mannix L, Adelman JU, Shechter A. Cardiac risk factors and the use of triptans: a survey study. Headache 2000; 40: 587–91.
- 35 Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477–84.
- 36 Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108–12.
- 37 Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8.
- 38 Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665–70.
- 39 Johnsen SP, Sørensen HT, Mellemkjoer L, Blot WJ, Nielsen GL, MsLaughlin JK, Olsen JH. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001; 86: 563–8.
- 40 Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113: 1578–87.
- 41 Geffen van ECG, Hulten van R, Bouvy ML, Egberts ACG, Heerdink ER. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008; 42: 218–25.
- 42
Obermann M,
Katsarava Z.
Triptan and ergotamine overuse in patients with headache at risk for vasoconstrictive complications.
Neurology
2006; 67: 1111.
10.1212/01.wnl.0000243634.66567.2e Google Scholar
